MOTIF BIO REVIVE-2 PHASE 3 STUDY RESULTS WITH ICLAPRIM PUBLISHED IN PEER-REVIEWED JOURNAL, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Iclaprim met the primary endpointIclaprim was well tolerated in the study, with no nephrotoxicity observedAdditional data from the previously announced results are included in the publication

May 1, 2018
Motif Bio plc

NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the results from REVIVE-2, a global Phase 3 clinical trial evaluating the investigational drug candidate iclaprim in patients with acute bacterial skin and skin structure infections (ABSSSI), have been published in the peer-reviewed journal, Antimicrobial Agents and Chemotherapyi. Positive results from this study were announced in October 2017 and presented at the recent 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018).

Press Release available here